Prostate cancer ranks as the second most common malignancy diagnosed among men worldwide. It manifest across a broad spectrum of presentations, ranging from localized low risk conditions to metastatic disease that is resistant to hormone therapy. Radiation therapy (RT) constitutes a significant therapeutic modality in the management of localized disease. While the use of RT in metastatic disease was previously quite limited, recent evidence demonstrates that RT can have positive effects beyond palliation, particularly in oligometastatic disease. Further research is needed to explore the systemic effects and immunological mechanisms of localized RT.